An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.
Takuro MizukamiKeiko MinashiHiroki HaraTomohiro NishinaYusuke AmanumaNaoki TakahashiAkio NakasyaMasaki TakahashiTakako Eguchi NakajimaPublished in: Investigational new drugs (2022)
The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary.